{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematological+Malignancies&page=5",
    "query": {
      "condition": "Hematological Malignancies",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1590,
    "total_pages": 159,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematological+Malignancies&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematological+Malignancies&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T11:08:23.439Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05118802",
      "title": "Measuring the Impact of MANNA s Medically Tailored Meal Program in Patients With a Non-terminal Cancer Diagnosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Interview",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2021-08-11",
      "completion_date": "2023-03-03",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05118802"
    },
    {
      "nct_id": "NCT03106428",
      "title": "A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Multiple Myeloma",
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "MEDI7247",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 67,
      "start_date": "2017-03-29",
      "completion_date": "2020-01-03",
      "has_results": false,
      "last_update_posted_date": "2020-02-28",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03106428"
    },
    {
      "nct_id": "NCT06093672",
      "title": "Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Polycythemia Vera"
      ],
      "interventions": [
        {
          "name": "Givinostat",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Italfarmaco",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2024-03-26",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Redlands, California • Englewood, Colorado + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06093672"
    },
    {
      "nct_id": "NCT07403812",
      "title": "Assessing DCog Short for Neurotoxicity in CAR-T",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neurotoxicity",
        "Neurotoxicity Syndromes",
        "Hematologic Malignancy",
        "Immune Effector Cell Associated Neurotoxicity Syndrome"
      ],
      "interventions": [
        {
          "name": "DCog Short",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-04-13",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07403812"
    },
    {
      "nct_id": "NCT01207128",
      "title": "Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Voriconazole, micafungin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-02",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-04-20",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01207128"
    },
    {
      "nct_id": "NCT03082677",
      "title": "Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloid Hematologic Malignancy",
        "Lymphoid Hematologic Malignancy"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-03-10",
      "completion_date": "2021-09-02",
      "has_results": true,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03082677"
    },
    {
      "nct_id": "NCT01375842",
      "title": "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors",
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 661,
      "start_date": "2011-06-21",
      "completion_date": "2018-09-30",
      "has_results": false,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 16,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375842"
    },
    {
      "nct_id": "NCT04888988",
      "title": "Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chemotherapy-Induced Peripheral Neuropathy",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Exercise Counseling",
          "type": "OTHER"
        },
        {
          "name": "Exercise Intervention",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Neuropathy Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Rochester NCORP Research Base",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2022-02-25",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 93,
      "location_summary": "Fresno, California • Martinez, California • Roseville, California + 70 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Martinez",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04888988"
    },
    {
      "nct_id": "NCT04184869",
      "title": "Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Hematological Malignancies"
      ],
      "interventions": [
        {
          "name": "Belinostat",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acrotech Biopharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2019-08-05",
      "completion_date": "2023-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-03",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04184869"
    },
    {
      "nct_id": "NCT05201183",
      "title": "A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Chronic Myeloid Leukemia",
        "Acute Lymphocytic Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Fludarabine + Total Marrow Irradiation",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Naoyuki G. Saito, M.D., Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2023-10",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2023-12-11",
      "last_synced_at": "2026-10-12T11:08:23.439Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05201183"
    }
  ]
}